Mike Magliochetti

Mike Magliochetti is an Operating Partner at Riverside Partners and has 30 years of successful healthcare operating and acquisition experience. Prior to joining Riverside, Mike served as CEO of Claros Diagnostics, a point-of-care in-vitro diagnostic firm, which was honored as one of the Top 50 Most Innovative Companies in the World for 2011 by MIT Technology Review; later acquired by OPKO Health. 

He previously served as CEO of RMH, a leading orthopedic products company, and as CEO of both HemaMetrics and UroSurge. He held senior positions with the medical device company Haemonetics and the polymer products company Delta Surprenant, and completed an assignment with the U.S. Army Research Command. In addition to serving on the Board of Overseers for Boston Museum of Science, hes serves on the Advisory Boards for Boston Children’s Hospital, Lahey Clinic and Medical Development Group-Boston. 

Mike has also served as an Adjunct Professor of Biomedical Engineering at the University of Iowa and consulted with several medical device and pharmaceutical companies.  Mike holds a Bachelor of Science degree in Chemical Engineering and a Master of Business Administration from Northeastern University, and a Ph.D. in Chemical Engineering from the University of Massachusetts at Amherst.